hackint0sh/New-Dataset huggingface dataset:
nctId: NCT06339671 id: PASSAGE briefTitle: Post-operative Complications and Smoking Habits in Colorectal Surgery acronym: PASSAGE overallStatus: NOT_YET_RECRUITING date: 2024-04-15 date: 2025-09-25 date: 2025-09-25 date: 2024-04-01 date: 2024-04-09 name: IRCCS Ospedale San Raffaele class: OTHER name: Ospedale San Paolo name: Ospedali Riuniti Marche Nord pesaro briefSummary: PASSAGE is a national multicenter retrospective and prospective observational cohort study in which patients who will undergo colorectal surgery will be enrolled. conditions: Colorectal Disorders studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: OTHER count: 1527 type: ESTIMATED measure: Incidence and severity of postoperative complications surgery in three groups measure: Incidence and severity of postoperative complications surgery in NF (non-smokers) group sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Prof. Pierpaolo Sileri city: Milan country: Italy name: Pierpaolo Sileri role: CONTACT lat: 45.46427 lon: 9.18951 hasResults: False
nctId: NCT06339658 id: TAD-ICG briefTitle: ICG vs Blue Patent as a Tracer in the Performance of TAD in Patients With cN1 Breast Carcinoma After Neoadjuvant Chemotherapy overallStatus: RECRUITING date: 2021-01-01 date: 2026-01-01 date: 2026-01-01 date: 2024-04-01 date: 2024-04-15 name: Hospital Universitari de Bellvitge class: OTHER briefSummary: To validate the use of ICG as a tracer during TAD in patients with cN1 breast carcinoma after neoadjuvant chemotherapy. conditions: Breast Cancer conditions: Axillary Metastases studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 43 type: ESTIMATED name: Targeted axillary dissection (TAD) by ICG name: Targeted axillary dissection (TAD) by Blue patent measure: Detection rate of sentinel lymph node measure: Detection rate of sentinel lymph node measure: Adverse effects sex: FEMALE minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Hospital de Bellvitge status: RECRUITING city: Hospitalet de Llobregat state: Barcelona zip: 08907 country: Spain name: Amparo Garcia-Tejedor, MDPhD role: CONTACT phone: 0034-660223417 email: agarciat@bellvitgehospital.cat lat: 41.35967 lon: 2.10028 hasResults: False
nctId: NCT06339645 id: P00003121 briefTitle: Intravesical Platelet-rich Plasma Injection in Patients With Interstitial Cystitis/Bladder-A Retrospective Study overallStatus: NOT_YET_RECRUITING date: 2024-04-01 date: 2024-05-22 date: 2024-12-31 date: 2024-04-01 date: 2024-04-01 name: Hualien Tzu Chi General Hospital class: OTHER briefSummary: The correlation of safety and effectiveness between intravesical platelet-rich plasma injection in patients with interstitial cystitis/bladder-A retrospective study to evaluate the correlation of safety and effectiveness between intravesical platelet-rich plasma injection of IC/BPS, with age of at least 20-84 years old in Taiwan of either sex with IC/BPS symptoms and proven of IC by cystoscopic hydrodistention. Patients who meet all eligibility requirements for entry into the study of intravesical PRP injection. conditions: Safety and Effectiveness Between Intravesical Platelet-rich Plasma Injection in Patients With Interstitial Cystitis/Bladder studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: RETROSPECTIVE count: 658 type: ESTIMATED name: PRP measure: Global response assessment (GRA) sex: ALL minimumAge: 20 Years maximumAge: 80 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Wan Ru Yu city: Hualien City state: Outside U.S./Taiwan zip: 970 country: Taiwan name: Wan Ru Yu role: CONTACT phone: 0925051013 email: wanzu666@gmail.com lat: 23.97694 lon: 121.60444 hasResults: False
nctId: NCT06339632 id: AVAP-NG 3363 briefTitle: Effects of Transcutaneous Electrical Phrenic Nerve Stimulation and Transcutaneous Electrical Diaphragmatic Stimulation overallStatus: RECRUITING date: 2024-04-01 date: 2024-12-01 date: 2025-03-01 date: 2024-04-01 date: 2024-04-18 name: Hospital Sirio-Libanes class: OTHER name: Hospital Israelita Albert Einstein briefSummary: Transcutaneous electrical phrenic nerve stimulation (TEPNS) and transcutaneous electrical diaphragm stimulation (TEDS) are modalities that use surface electrodes placed on the patients' skin to generate action potentials and contractions of the muscle fibers of the diaphragm. The primary objective will be to evaluate the efficacy of TEPNS and TEDS in healthy adult individuals. Secondary objectives will be to assess the feasibility, safety, and level of discomfort reported by the individual resulting from the application of TEPNS and TEDS. conditions: Diaphragm studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: CROSSOVER primaryPurpose: TREATMENT masking: SINGLE maskingDescription: The researchers responsible for assessing diaphragm muscle through ultrasound will perform image recordings and captures during the "TEPNS" and "TEDS" intervention moments. Subsequently, the images will be analyzed by a blinded evaluator for the adopted intervention. The analyses will follow the methods described in the "diaphragm muscle mobility" and "diaphragm muscle thickness and thickening fraction" sections. Study participants will also be instructed not to disclose information regarding their experience and sensations during the intervention period, ensuring study blinding. whoMasked: OUTCOMES_ASSESSOR count: 12 type: ESTIMATED name: Transcutaneous electrical phrenic nerve stimulation (TEPNS) name: Transcutaneous electrical diaphragm stimulation (TEDS) measure: Diaphragm mobility measure: Diaphragm thickness measure: Thickening fraction measure: Evaluation of sensory discomfort measure: Safety of TEPNS and TEDS application sex: ALL minimumAge: 18 Years maximumAge: 60 Years stdAges: ADULT facility: Hospital Sírio Libanês status: RECRUITING city: São Paulo zip: 01308-050 country: Brazil name: Renato F RIGHETTI, PhD role: CONTACT phone: 5511987496664 email: refragar@gmail.com name: Renato F Righetti, PhD role: PRINCIPAL_INVESTIGATOR name: Wellington P Yamaguti, PhD role: SUB_INVESTIGATOR name: Ricardo K Nawa, PhD role: SUB_INVESTIGATOR lat: -23.5475 lon: -46.63611 hasResults: False
nctId: NCT06339619 id: SYSKY-2023-1262-02 briefTitle: Combination Immunotherapy of Adebrelimab With Apatinib and Tegafur for Immune Rechallenge Therapy in Esophageal Squamous Cell Carcinoma overallStatus: RECRUITING date: 2024-03-11 date: 2026-03-01 date: 2026-09-01 date: 2024-04-01 date: 2024-04-01 name: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University class: OTHER briefSummary: The goal of this single-arm study is to explore the efficacy and safety of Adebrelimab in combination with Apatinib and Tegafur for the treatment of locally advanced or metastatic esophageal squamous cell carcinoma that has failed first-line standard treatment with PD-1 inhibitors in combination with chemotherapy. conditions: Locally Advanced or Metastatic Esophageal Squamous Cell Carcinoma studyType: INTERVENTIONAL phases: PHASE2 allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: TREATMENT masking: NONE count: 32 type: ESTIMATED name: Adebrelimab name: Apatinib name: Tegafur measure: Objective response rate (ORR) measure: Progression-free survival (PFS) measure: Overall survival (OS) measure: ≥Grade 3 AEs sex: ALL minimumAge: 18 Years maximumAge: 75 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University status: RECRUITING city: Guangzhou state: Guangdong zip: 510030 country: China name: Minghui Wang, Dr. role: CONTACT phone: 13826276828 email: wmingh@mail.sysu.edu.cn name: Minghui Wang, Dr. role: PRINCIPAL_INVESTIGATOR lat: 23.11667 lon: 113.25 hasResults: False
nctId: NCT06339606 id: 4316 briefTitle: Pregnancy Repository acronym: PR overallStatus: NOT_YET_RECRUITING date: 2024-05-01 date: 2026-04-30 date: 2031-04-30 date: 2024-04-01 date: 2024-04-24 name: Sunnybrook Health Sciences Centre class: OTHER briefSummary: An essential part of clinical research is the availability and accessibility of human biospecimens for the identification of biomarkers, new treatments and measurement of response to therapy. Proteins, RNA and DNA can be extracted and studied as well. This is a critical first step in performing many fundamental molecular biology experiments. A variety of biospecimens are utilized for research including but not limited to normal and malignant tissues, blood, and other body fluids.
In order to obtain high-quality biospecimens, they must be acquired serially, stored according to current standards, and matched with clinical information for maximum value. As such, the investigators would like to create a repository of biospecimens collected from pregnant patients who are seen at Mount Sinai Hospital and other research hospitals in Toronto. Mount Sinai provides personnel and infrastructure to serve the largest (7500 births/year) and highest complex Maternity program in Ontario. Of the 7500 patients a year, at least 2500 are considered high risk pregnancies, where there's a possibility of preeclampsia, placenta accreta and a host of other complications. For this study, biological specimens - blood, cervical and placental samples - will be collected from these high-risk groups in order to better understand the causes of the underlying conditions. conditions: Pregnancy Related conditions: Fetal Growth Retardation conditions: Placental Insufficiency conditions: Preeclampsia conditions: Cervix; Pregnancy studyType: OBSERVATIONAL observationalModel: CASE_CONTROL timePerspective: PROSPECTIVE count: 7000 type: ESTIMATED name: Biospecimen collection measure: Biomarker levels measure: Pathology sex: FEMALE minimumAge: 18 Years maximumAge: 45 Years stdAges: ADULT hasResults: False
nctId: NCT06339593 id: 2023-0391 briefTitle: Regional Monitoring of CF Lung Disease overallStatus: RECRUITING date: 2024-01-05 date: 2028-01 date: 2028-01 date: 2024-04-01 date: 2024-04-01 name: Children's Hospital Medical Center, Cincinnati class: OTHER briefSummary: The main reason for this research study is to learn more about some new tests that are being developing for patients with Cystic Fibrosis (CF) to measure changes in the lungs. In this study, the focus will be to learn how stopping Airway Clearance (ACT) and re-starting ACT can affect these tests. These new tests include using a breathable gas called Xenon (Xe) with MRI (magnetic resonance imaging) to improve the pictures of changes in the lungs. The Xenon (Xe) gas that has been treated to have a larger MRI signal (also called hyperpolarized). The other new test is called LCI (Lung Clearance Index) that can measure how well the lungs are working. The MRI machine used in this study has been approved by the U.S. Food and Drug Administration (FDA) and is commercially available for sale in the USA. Hyperpolarized Xe gas is an FDA-approved, inhaled contrast agent for lung ventilation MRI. The new Xe MRI techniques that are being developed and used for this research study are investigational, meaning these new Xe MRI techniques are not FDA approved, but they are similar to FDA-approved techniques that are used clinically at Cincinnati Children's Hospital Medical Center (CCHMC). Xe gas and the new MRI techniques used in this research study have been used for many years in research, including in many research studies conducted at CCHMC like this one. conditions: Cystic Fibrosis studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 80 type: ESTIMATED name: Hyperpolarized Xe129 measure: Assessing structural and functional lung abnormalities via Xenon MRI measure: Assessing patients who have self-withdrawn airway clearance treatment to determine ventilation abnormalities. measure: Change in Xenon Ventilation Defect Process (VDP) sex: ALL minimumAge: 12 Years maximumAge: 21 Years stdAges: CHILD stdAges: ADULT facility: Cincinnati Children's Hospital status: RECRUITING city: Cincinnati state: Ohio zip: 45229 country: United States name: Carrie Stevens, BS role: CONTACT phone: 513-636-9973 email: carrie.stevens@cchmc.org lat: 39.12713 lon: -84.51435 hasResults: False
nctId: NCT06339580 id: 324456 briefTitle: Assessment of Volume-targeted Ventilation in Patients With Neuromuscular Disease acronym: VT-NMD overallStatus: NOT_YET_RECRUITING date: 2024-04 date: 2026-03 date: 2026-04 date: 2024-04-01 date: 2024-04-25 name: Guy's and St Thomas' NHS Foundation Trust class: OTHER briefSummary: Assessment of safety and efficacy of volume-targeted ventilation in patients with neuromuscular disease. conditions: Neuromuscular Diseases studyType: INTERVENTIONAL phases: PHASE2 allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: TREATMENT masking: NONE count: 30 type: ESTIMATED name: Volume-targeted non-invasive ventilation measure: Mean overnight transcutaneous carbon dioxide measure: Maximum overnight transcutaneous carbon dioxide measure: Overnight desaturation index measure: Visual analogue scale of sleep comfort measure: Health-related quality of life measure: Adherence to ventilation sex: ALL minimumAge: 18 Years maximumAge: 80 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Guy's and St. Thomas NHS Foundation Trust city: London zip: SE1 7EH country: United Kingdom lat: 51.50853 lon: -0.12574 facility: Guy's & St Thomas' NHS Foundation Trust city: London zip: SE1 9RT country: United Kingdom lat: 51.50853 lon: -0.12574 hasResults: False
nctId: NCT06339567 id: 671_Hemo-PCOS briefTitle: Evaluation of the Venous Thrombotic Biological Profile of Different PCOS Phenotypes: French Cross-sectional Study acronym: Hemo-PCOS overallStatus: RECRUITING date: 2024-02-08 date: 2026-02-07 date: 2029-02-07 date: 2024-04-01 date: 2024-04-01 name: Fondation Hôpital Saint-Joseph class: OTHER briefSummary: Polycystic ovary syndrome (PCOS) is the most common endocrine disorder of women of childbearing age. PCOS can be individualized into several phenotypes, taking into account in particular the presence of hyperandrogenism, insulin resistance and BMI. Hyperandrogenism and insulin resistance appear to be important factors in the development of cardiovascular cardiovascular disease. In addition, patients frequently use anti-androgenic and/or contraceptive treatments contraceptives, such as combined hormonal contraception (CHC), the use of which is associated with an increased cardiovascular and thrombo and venous thrombosis (VTE). A meta-analysis published in 2020 by Gariani et al.
based on three large studies, estimated the risk of VTE in women with PCOS after adjustment for obesity and hormone therapy. This risk was significantly higher compared with women without PCOS (pooled OR 1.89, CI95% 1.60-2.24). No study has looked specifically investigated the risk of VTE according to different PCOS phenotypes. Such data would be very useful in clinical practice, as it would enable monitoring, contraceptive treatment and anti-androgenic anti-androgen treatment according to the PCOS phenotype, while limiting risks. Assessing the differences PCOS phenotypes is limited by the large sample size required. required. VTE is a rare event in women of childbearing age, and the number of PCOS phenotypes is high.
PCOS phenotypes. Intermediate markers of VTE risk are used in these situations. These markers are thrombin generation tests (notably ETP) and their sensitivity to activated protein C (nAPCsr) and thrombomodulin (nTMsr), as well as sex-hormone binding globulin (SHBG). conditions: Polycystic Ovary Syndrome studyType: INTERVENTIONAL phases: NA allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: DIAGNOSTIC masking: NONE count: 320 type: ESTIMATED name: Thrombotic profile measure: biological procoagulant profile measure: Insuline resistance and weight measure: comparison of procoagulant profile depending on insulin resistance measure: comparison of procoagulant profile depending on hyperangrogenism measure: comparison of procoagulant profile depending on PCOS phenotype measure: comparison of procoagulant profile depending on AMH Rate measure: comparison of QoL score depending on PCOS phenotype sex: FEMALE minimumAge: 18 Years maximumAge: 35 Years stdAges: ADULT facility: Hôpital Paris Saint Joseph status: RECRUITING city: Paris country: France name: Juliette COURTIADE MAHLER role: CONTACT email: jcourtiade@ghpsj.fr name: Hélène Beaussier, pharmaD role: CONTACT email: hbeaussier@ghpsj.fr lat: 48.85341 lon: 2.3488 hasResults: False
nctId: NCT06339554 id: 4806 briefTitle: Alectinib-induced Endocrine Toxicity acronym: TOSS-ALK overallStatus: COMPLETED date: 2018-10-12 date: 2023-10-30 date: 2023-10-30 date: 2024-04-01 date: 2024-04-01 name: Fondazione Policlinico Universitario Agostino Gemelli IRCCS class: OTHER briefSummary: The experimental Cohort A (male ALK+ ANSCLC patients receiving alectinib), the control Cohort B (female ALK+ ANSCLC patients receiving alectinib) and control Cohort C (male NON-ALK ANSCLC patients) were prospectively evaluated for full hormone assessment of androgen deficiency, AT 8 weeks after treatment start and in case of reported suspected symptoms. Patients with major sexual dysfunctions were referred to endocrinologist. conditions: NSCLC Stage IV studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 98 type: ACTUAL name: Alectinib 150 MG [Alecensa] measure: Incidence of endocrine toxicity in overall ALK-positive measure: Incidence of symptomatic hypogonadism in male ANSCLC patients sex: ALL minimumAge: 18 Years maximumAge: 70 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Fondazione Policlinico Gemelli IRCCS city: Rome zip: 00168 country: Italy lat: 41.89193 lon: 12.51133 hasResults: False
nctId: NCT06339541 id: 029-FPO23 briefTitle: The ACC Preclinical Research Platform for Precision Oncology acronym: ACC Platform overallStatus: RECRUITING date: 2023-06-05 date: 2024-06-01 date: 2024-12-01 date: 2024-04-01 date: 2024-04-01 name: Fondazione del Piemonte per l'Oncologia class: OTHER name: Alleanza Contro il Cancro briefSummary: The ACC Preclinical Research Platform for Precision Oncology is a retrospective and prospective observational study focused on the implementation and validation of the application of PDCM (Patient Derived Cancer Models) generated from tissues or cells of patients with neoplastic disease, as a tool to improve molecular and biological knowledge of tumours and to test the efficacy and sensitivity of pharmacological treatments. conditions: Solid Tumor conditions: Hematologic Neoplasms studyType: OBSERVATIONAL observationalModel: CASE_ONLY timePerspective: OTHER count: 250 type: ESTIMATED measure: number of PDCM (patient derived cancer models) measure: number of Whole Exome Sequencing (WES) e RNA-seq performed measure: number of PDCM shared within the network sex: ALL minimumAge: 14 Years stdAges: CHILD stdAges: ADULT stdAges: OLDER_ADULT facility: Fondazione del Piemonte per l'Oncologia-IRCCS Candiolo status: RECRUITING city: Candiolo state: Turin zip: 10060 country: Italy name: Marco Asioli, BSc role: CONTACT phone: +390119933463 email: marco.asioli@ircc.it name: Enzo Medico, MD role: PRINCIPAL_INVESTIGATOR lat: 44.95858 lon: 7.59812 hasResults: False
nctId: NCT06339528 id: EK-VPl421012021 briefTitle: Potential of Vojta's Reflex Locomotion as a Pre/Induction Method for Uterine Activity: a Pilot Study overallStatus: COMPLETED date: 2021-06-23 date: 2024-01-01 date: 2024-03-01 date: 2024-04-01 date: 2024-04-08 name: Faculty Hospital Kralovske Vinohrady class: OTHER_GOV briefSummary: The Vojta's method is neurophysiological rehabilitation method used to support and induce reflex responses of locomotor and vegetative system. It uses involuntary motor reaction of the body during pressure stimulation of so-called trigger zones. Pregnancy is currently considered a contraindication for using Vojta's therapy to potential risks of inducing regular uterine activity and risk of delivery. The aim of the study is to evaluate changes in uterine activity and also explore the possibility of using this method as a new approach for pre/induction of delivery. conditions: Induced Vaginal Delivery studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: A total of 40 pregnant patients between 40+0 to 41+0 weeks of gestational age were randomly selected for this study. Stimulation of trigger zones according to Vojta's therapy was applied to 20 of them by a team of licensed physiotherapists while a control group received a sham stimulation carried out by physicians. Cardiotocographic (CTG) recordings were conducted right before and immediately after stimulation. CTG recordings were subsequently blindly evaluated by 2 independent obstetricians. primaryPurpose: TREATMENT masking: TRIPLE maskingDescription: Stimulation of trigger zones according to Vojta's therapy was applied to 20 of them by a team of licensed physiotherapists while a control group received a sham stimulation carried out by physicians. Cardiotocographic (CTG) recordings were conducted right before and immediately after stimulation. CTG recordings were subsequently blindly evaluated by 2 independent obstetricians. Patients did not know if clinician have skills to stimulate properly according to the Vojta's Reflex Locomotion. whoMasked: PARTICIPANT whoMasked: CARE_PROVIDER whoMasked: OUTCOMES_ASSESSOR count: 40 type: ACTUAL name: Vojta's Reflex Locomotion name: Sham stimulation measure: Cardiotocographic (CTG) recordings - measure: subjective perception during stimulation sex: FEMALE minimumAge: 18 Years maximumAge: 45 Years stdAges: ADULT facility: Faculty Hospital Kralovske Vinohrady city: Praha zip: 11000 country: Czechia lat: 50.08804 lon: 14.42076 hasResults: False
nctId: NCT06339515 id: DuzceU-SBF-NYS-02 briefTitle: Teaching School Health Nursing Course With Universal Design Model overallStatus: NOT_YET_RECRUITING date: 2024-03-21 date: 2024-06-06 date: 2025-12-01 date: 2024-04-01 date: 2024-04-01 name: Duzce University class: OTHER briefSummary: The aim of this study is to design, implement and evaluate the School Health Nursing course in the undergraduate nursing program using the universal design model. conditions: Nursing Education studyType: INTERVENTIONAL phases: NA allocation: NA interventionModel: SINGLE_GROUP interventionModelDescription: Universal Design Model for Learning primaryPurpose: OTHER masking: NONE count: 27 type: ESTIMATED name: Universal Design Model measure: Critical Thinking Disposition Scale measure: Communication Skills Scale measure: Healthy Living Awareness sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Nuriye Yıldırım city: Düzce state: Duzce zip: 81620 country: Turkey name: Atiye Erbaş, PhD role: CONTACT phone: +90380 542 11 41 phoneExt: 3533 email: atiyeerbas@duzce.edu.tr name: PhD role: CONTACT name: Nuriye Yıldırım Şişman, PhD role: SUB_INVESTIGATOR name: Fahriye Hayırsever, PhD role: PRINCIPAL_INVESTIGATOR lat: 40.83889 lon: 31.16389 hasResults: False